In critically ill COVID-19 patients, compared with healthy subjects, decreased prekallikrein and high molecular weight kininogen levels, as well as increased kallikrein–C1 inhibitor complexes, in plasma were reported, reflecting activation of the kallikrein–kinin system [127]. This evidence concerns the gene KNG1 and COVID-19.